Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „week“
Suchtreffer
Begriffe & Kennungen
Abilify Maintena · 4.8 · Weight During the double-blind, active-controlled phase of the 38-week long-term trial (see section 5.1), the
Eintrag öffnenAbilify Maintena · 4.8 · Weight During the double-blind, active-controlled phase of the 38-week long-term trial (see section 5.1), the
Eintrag öffnenAbrysvo · 4.5 · A minimum interval of two weeks is recommended between administration of Abrysvo and administration of a tetan
Eintrag öffnenAbrysvo · 4.8 · The safety of administering a single dose of Abrysvo to pregnant individuals at 24-36 weeks of gestation and i
Eintrag öffnenAdcetris · 4.8 · 18 peripheral neuropathy was 8 weeks. Patients who discontinued due to peripheral neuropathy received a median
Eintrag öffnenAdcetris · 4.8 · Severe and prolonged (≥ 1 week) neutropenia can occur with this treatment which may increase the risk of patie
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · 10 were treated with placebo, for 24 weeks. The most common AEs, occurring in ≥ 2 patients treated with tadala
Eintrag öffnenAdempas · 4.8 · 11 to 16 weeks (see section 4.2), followed by an optional long-term extension phase. Most common adverse react
Eintrag öffnenAdtralza · 4.8 · 6 The rate of conjunctivitis in the initial 16 weeks treatment period was 22.0 events/100 patient years of exp
Eintrag öffnenAdtralza · 4.8 · 7 The rate of injection site reactions in the initial 16 weeks treatment period was 51.5 events/100 patient ye
Eintrag öffnenAdtralza · 4.8 · In ECZTRA 1, ECZTRA 2, ECZTRA 3, and the vaccine-response study, the incidence of ADA up to 16 weeks was 1.4%
Eintrag öffnenAdtralza · 4.8 · The long-term safety of tralokinumab was assessed in 2 monotherapy studies up to 52 weeks, and in a combinatio
Eintrag öffnenAimovig · 4.8 · Cutaneous and hypersensitivity reactions In the integrated 12-week placebo-controlled phase of the studies, no
Eintrag öffnenAimovig · 4.8 · Injection site reactions In the integrated 12-week placebo-controlled phase of the studies, injection site rea
Eintrag öffnenAimovig · 4.8 · Table 1 lists all adverse drug reactions that occurred in Aimovig-treated patients during the 12-week placebo-
Eintrag öffnenAldara · 4.8 · In clinical trials of imiquimod cream 3 times weekly for 4 or 8 weeks the most frequently occurring applicatio
Eintrag öffnenAldara · 4.8 · In the pivotal trials with 3 times a week dosing, the most frequently reported adverse drug reactions judged t
Eintrag öffnenAldara · 4.8 · In trials with 5 times per week dosing 58% of patients experienced at least one adverse event. The most freque
Eintrag öffnenAldurazyme · 4.8 · In a phase 4 study 33 MPS I patients received 1 of 4 dose regimens: 100 U/kg IV every week (recommended dose),
Eintrag öffnenAnzupgo · 4.8 · Application site reactions In the pool of three vehicle-controlled clinical studies through 16 weeks, 9 applic
Eintrag öffnen